Organization | SRC Bioclinicum

SRC Bioclinicum Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial

2012

NCT01759810

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2012

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 3 Trials (5)

allogeneic hematopoietic stem cells (Hemacord) (3 trials)

autologous hematopoietic cell (3 trials)

cytolytic t-lymphocytes (3 trials)

dendritic cells loaded with brain metastases (3 trials)

dendritic cells loaded with glioblastoma (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Glioblastoma (Phase 3)

Lung Neoplasms (Phase 3)

Neoplasm Metastasis (Phase 3)

Neoplasms, Second Primary (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial APIs: 5